The antibody was purified by affinity chromatography.
Concentration:
0.5 mg/ml
Storage & Handling:
The antibody solution should be stored undiluted at 4°C.
Application:
FC
Recommended Usage:
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:
Additional reported applications (for the relevant formats) include: The DJR2-2 antibody is useful for immunofluorescent staining and flow cytometric analysis of DR5/TRAIL-R2 receptor expression. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated anti-mouse IgG second step (Cat. No. 405303), followed by SAv-PE (Cat. No. 405204)).
Application References:
1. Uno, K., et al., 2003. Blood 101: 3658. 2. Sato, K., et al., 2005. J. Immunol. 174:4025. 3. Shi, J., et al. 2008. Blood. 111:1309.PubMed
Human peripheral blood lymphocytes stained with purified DJR2-2, followed by biotinylated anti-mouse IgG and Sav-PE
Description:
DR5 is 55 kD member 10B of the TNF receptor superfamily (TNFRSF10B), also known as TRAIL-R2, TRICK2, KILLER, and CD262. It binds the cytotoxic ligand TRAIL and induces apoptosis. The DR5 receptor is broadly expressed on a variety of normal tissues and many tumors. DR5 expression has been reported to be upregulated in human cells by interferon-α, 2-methoxyestradiol, and paclitaxel, and downregulated by adenoviral E3 proteins.
Other Names:
TRAIL-R2, KILLER, TRICK2, TNFRSF10B, Ly98, CD262
Structure:
TNFR superfamily, 55 kD
Distribution:
Broadly expressed on normal and tumor cells
Function:
Induces apoptosis
Ligand Receptor:
TRAIL
Antigen References:
1. MacFarlane, M., et al., 1997. J. Biol. Chem. 272:25417. 2. Walczak, H., et al., 1997. EMBO J. 16:5386. 3. Shigeno, M., et al., 2003. Oncogene 22:1653. 4. LaVallee, T., et al., 2003. Cancer Res. 63:468. 5. Nimmanapalli, R., et al., 2001. Cancer Res. 61:759
